Sorrento rises 6% as FDA OKs phase 2 study of monoclonal antibody for carcinoma
April 27 2021 - 12:25PM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024